Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis

References

• Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Eng J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Gordon L I, Harrington D, Anderson J, Colgan J, Glick J, Neiman R, et al. Comparison of a second generation combination chematherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced non-Hodgkin's lymphoma. N Eng J Med 1991; 327: 1342–1349
   Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Eng J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Habermann T M, Weller E, Morrison V A, Cassileth P A, Cohn J, Dakhil S, et al. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): an update. Blood 2004; 104
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Truemper L, Gill D, Osterborg A, Pettengell R, Trneny M, et al. First analysis of the completed Mabthera International (Mint) trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL). Blood 2004; 104: 157
   Google Scholar
• Salven P, Orpana A, Teerenhovi L, Joensuu H, et al. Simultaneous elevation in the serum concentration of the angiogenic growth factors and bFGF is an independent predictor of poor prognosis in non-Hodgkin's lymphoma: a single-institution study of 200 patients. Blood 2000; 96: 3712–3718
   PubMed Web of Science ®Google Scholar
• Lossos I S, Alizadeh A A, Eisen M B, Chan W C, Brown P O, Botstein D, et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proceedings of the National Academy of Sciences (USA) 2000; 97: 10209–10213
   PubMed Web of Science ®Google Scholar
• Hazar B, Paydas S, Zorludemir S, Sahin B, Tuncer I, et al. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leukemia & Lymphoma 2003; 44: 2089–2093
   PubMed Web of Science ®Google Scholar
• Strebel B, Chott A, Huber D, Exner M, Jager U, Wagner O, et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Eng J Med 2004; 351: 250–259
   PubMed Web of Science ®Google Scholar
• Masood R, Cai J, Zheng T, Smith D I, Hinton D R, Gill P S, et al. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001; 98: 1904–1913
   PubMed Web of Science ®Google Scholar
• Wang E S, Teruya-Feldstein J, Wu Y, Zhu Z, Hicklin D J, Moore M A, et al. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004; 104: 2893–2902
   PubMed Web of Science ®Google Scholar
• Stopeck A, Iannone M, Rimsza L, Miller T, Fisher R, Bellamy W, et al. Expression of VEGF, VEGF receptors, and other angiogenic markers in relapsed aggressive non-Hodgkin's lymphoma: correlative studies from the SWOG S0108 trial. Blood 2004; 104, abst 2288
   Web of Science ®Google Scholar
• Presta L G, Chen H, O'Connor S J, Chisholm V, Meng Y G, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593–4599
   PubMed Web of Science ®Google Scholar
• Ryan A M, Eppler D B, Hagler K E, Bruner R H, Thomford P J, Hall R L, et al. Preclinical safety evaluation of bevacizumab, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 1999; 27: 78–86
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for metastatic colorectal cancer. N Eng J Med 2004; 350: 2335–2342
   PubMed Web of Science ®Google Scholar
• Sandler A B, Gray R, Brahmer J, Dowlati A, Schiller J H, Perry M C, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial E4599. Proc of ASCO 2005, Abst# LBA4
   Google Scholar
• Miller K D, Wang M, Gralow J, et al. E2100: a randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Proc of ASCO 2005
   Google Scholar
• Giantonio B J, Catalano P J, Meropol N J, O'Dwyer P J, Mitchell E P, Alberts M A, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc of ASCO 2005, Abst# 2
   Google Scholar
• Weidner. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. breast. Breast Cancer Res Treat 1995; 36: 169–180
   PubMed Web of Science ®Google Scholar
• Ribatti D, Vacca A, Marzullo A, Nico B, Ria R, Roncali L, Dammacco F. Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Int J Cancer 2000; 85: 171–175
   PubMed Web of Science ®Google Scholar
• Cox D R. Analysis of binary data. Methuen and Co, London 1970
   Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958; 53: 457–481
   Web of Science ®Google Scholar
• Smolej L, Andrys C, Maisnar V, Pour L, Maly J, et al. Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders. Acta Medica 2005; 48: 57–58
   Google Scholar
• Ribas C, Colleoni G W, Silva M R, Carregoza M J, Bordin Jo, et al. Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma. Eur J Haemotol 2004; 73: 311–317
   PubMed Web of Science ®Google Scholar
• Pedersen L M, Klausen T W, Davidsen U H, Johnsen H E, et al. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. Ann Hemat 2005; 84: 510–516
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Eng J Med 1999; 341: 1565
   PubMed Web of Science ®Google Scholar
• Dmoszynska A, Podhorecka M, Manko J, Bojarska-Junak A, Rolinski J, Skomra D, et al. The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma. Neoplasm 2005; 52: 175–181
   PubMed Web of Science ®Google Scholar
• Zhao W L, Mourah S, Mounier N, Leboeuf C, Daneshpouy M E, Legres L, et al. Vascular endothelial growth factor – A in expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Laboratory Investigations 2004; 84: 1512–1519
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocrinol Rev 2004; 25: 581–611
   PubMed Web of Science ®Google Scholar
• Dvorak H F, Detmar M, Claffey K P, Nagy J A, Van de Water L, Senger D R, et al. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Inter Arch Allergy Immunol 1995; 107: 233–235
   PubMed Web of Science ®Google Scholar
• Ho C, Sheu L, Li C, et al. Immunohistochemical expression of Basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin's lymphoma. Applied Immunohistochemistry and Molecular Morphology 2002; 10: 316–321
   Web of Science ®Google Scholar
• Niitsu N, Okamoto M, Nakamine H, Yoshino T, Tamaru J, Nakamura S, et al. Simultaneous elevation of the serum concentration of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol 2004; 68: 91–100
   Web of Science ®Google Scholar
• Pham C D, Roberts T P, van Bruggen N, Melnyk O, Mann J, Ferrara N, et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 1998; 16: 225–230
   PubMed Web of Science ®Google Scholar
• Margolin K, Gordon M S, Holmgren E, Gaudreault J, Novotny W, Fyfe G, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J Clin Oncol 2001; 19: 851–856
   PubMed Web of Science ®Google Scholar
• Gordon M S, Margolin K, Talpaz M, Sledge G W, Jr, Holmgren E, Benjamin R, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843–845
   PubMed Web of Science ®Google Scholar
• Stopeck A T, Bellamy W, Unger J, Rimsza L, Iannone M, Fisher R I, et al. Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group Study S0108. Proc of ASCO 2005, abst #6592
   Google Scholar
• Herbst R S, Johnson D H, Mininberg E, Carbone D P, Henderson T, Kim E S, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small cell lung cancer. J Clin Oncol 2005; 23: 1–10
   PubMed Web of Science ®Google Scholar